Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals.
Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products (ABZENA inside), through to clinical development.
Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena. Abzena’s technologies and services are provided across its three sites as follows:
Cambridge, UK (Babraham Research Campus), is the main location of our immunology, protein engineering, bioassays, bioanalytics, cell line development and bioconjugation activities. It is Abzena’s global headquarters; housing our commercial, finance and investor relations teams.
San Diego, CA, USA is home to Abzena’s GMP biopharmaceutical manufacturing plant for Phase I and II clinical trials. Cell banking, process development, batch analysis, QC release and regulatory assistance are all provided at this site for both WAVE and single-use bioreactors.
Abzena’s team in Bristol, PA, USA has a strong background in synthetic organic chemistry and expertise in bioconjugation; providing research chemistry, antibody drug conjugate (ADC) services and manufacture of GMP reagents. The company’s manufacturing capabilities in Bristol is being expanded to enable the manufacture of bioconjugates to GMP standards.
Alacrita is life science consulting for a networked age. You can expect the caliber and capabilities of a top-ranked consulting firm, but you'll find a difference in our expertise. We've built our team carefully, hand-picking only those consultants with deep domain knowledge and senior business experience. With more than 200 successful client assignments each year, we're proving what's possible for commercial life sciences in a new era of opportunity.
Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Our products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide. With over 25 years’ experience in the biopharmaceutical industry, we have the scientific, technical and regulatory expertise needed to support companies in moving faster to market with superior biotherapeutics. We also use this expertise to strengthen our own drug pipeline. Albumedix is a global company and fully owned subsidiary of Novozymes A/S.
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally.
Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.
What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.
Whether you need one-off consultancy support, clinical SOP implementation, expert medical or scientific input on a short or long term basis, or a full trial programme, we’d love to hear from you.
Arcinova are an agile and flexible Contract Development and Manufacturing Organisation (CDMO) that serves pharmaceutical and biotechnology companies across the globe. We offer a wide range of services from our world-class 15,000m2 facility situated in the North of England. Having a breadth of expertise under one roof enables us to deliver a collaborative approach to the development and manufacture of drug substance and drug products. With decades of experience, we are helping companies to develop life changing medicines and take them to market quickly and efficiently.
The extensive experience we gained working for over 20 years as part of one of the top 5 pharma companies has given us a unique insight into fulfilling client needs. Our wide range of services can support clients across the drug development pathway and includes expertise in drug substance synthesis and manufacturing scale up, drug product manufacture, bioanalytical services and radiolabelling synthesis.
Astex Pharmaceuticals, Inc. is an international, NASDAQ-listed (ASTX) pharmaceutical company dedicated to the discovery and development of novel therapeutics with a focus on oncology.
Athena Market Access Solutions
Founded in 2016 Athena Market Access Solutions specialises in providing pricing and reimbursement related solutions to organisations in the life sciences industry.
The company is run by Maximilian Lebmeier who has over a decade experience in Global, European and UK/Irish market access roles in the pharmaceutical industry. He has worked on over 130 health technology assessments (HTAs) in a wide range of disease areas including rheumatology, dermatology, cardiology, hepatology, transplantation, infectious diseases, and oncology. Besides of his company duties he has worked intensively with industry associations on market access and HTA related activities.
Athena’s services stretch throughout the lifecycle of a product from payer and reimbursement input into clinical development, early health economics and outcomes research and pricing activities alongside clinical trials and regulatory processes, the preparation of reimbursement submissions, the navigation of pricing and reimbursement procedures, input into clinical guidelines, market access and competitive pipeline and portfolio reviews, training and strategic consultancy.
Athena Market Access Solutions Ltd. is co‐organiser of the ‘Kendal Collaboration’, a group of small businesses and independent professionals with expertise in all aspects of health economics and outcomes research.
Athena’s customers include biotechnology companies, pharmaceutical companies, as well as a consultancies.